The Medication(s) listed below have been approved by the Food & Drug Administration (FDA) as orphan products for treatment of this condition. There may be other products available
that are not considered orphan products.
Riluzole oral suspension (Brand name: Tiglutik)
- Manufactured by
FDA-approved indication: September 2018, riluzole oral suspension (Tiglutik) was approved for the treatment of amyotrophic lateral sclerosis (ALS).
National Library of Medicine Drug Information Portal